Exact Sciences Corporation (EXAS)


-2.32 (-4.70%)
Symbol EXAS
Price $47.05
Beta 1.307
Volume Avg. 2.13M
Market Cap 8.326B
Shares () -
52 Week Range 35.34-108.99
1y Target Est -
DCF Unlevered EXAS DCF ->
DCF Levered EXAS LDCF ->
ROE -22.07% Sell
ROA -11.41% Sell
Operating Margin -
Debt / Equity 100.58% Buy
P/E -
P/B 2.59 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest EXAS news

Mr. Kevin Conroy
Diagnostics & Research
NASDAQ Global Select

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.